Cargando…

Costs in inflammatory bowel diseases

Variables influencing total direct medical costs in inflammatory bowel diseases include country, diagnosis (generally, patients with Crohn's disease generated higher costs compared with patients with ulcerative colitis), and year since diagnosis. In all studies the mean costs were higher than t...

Descripción completa

Detalles Bibliográficos
Autores principales: Petryszyn, Paweł W., Witczak, Izabela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814543/
https://www.ncbi.nlm.nih.gov/pubmed/27110304
http://dx.doi.org/10.5114/pg.2016.57883
_version_ 1782424436443447296
author Petryszyn, Paweł W.
Witczak, Izabela
author_facet Petryszyn, Paweł W.
Witczak, Izabela
author_sort Petryszyn, Paweł W.
collection PubMed
description Variables influencing total direct medical costs in inflammatory bowel diseases include country, diagnosis (generally, patients with Crohn's disease generated higher costs compared with patients with ulcerative colitis), and year since diagnosis. In all studies the mean costs were higher than the median costs, which indicates that a relatively small group of the most severely ill patients significantly affect the total cost of treatment of these diseases. A major component of direct medical costs was attributed to hospitalisation, ranging from 49% to 80% of the total. The costs of surgery constituted 40–61% of inpatient costs. Indirect costs in inflammatory bowel diseases, unappreciated and often underestimated (considered by few authors and as a loss of work), are in fact important and may even exceed direct medical costs.
format Online
Article
Text
id pubmed-4814543
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-48145432016-04-22 Costs in inflammatory bowel diseases Petryszyn, Paweł W. Witczak, Izabela Prz Gastroenterol Review Paper Variables influencing total direct medical costs in inflammatory bowel diseases include country, diagnosis (generally, patients with Crohn's disease generated higher costs compared with patients with ulcerative colitis), and year since diagnosis. In all studies the mean costs were higher than the median costs, which indicates that a relatively small group of the most severely ill patients significantly affect the total cost of treatment of these diseases. A major component of direct medical costs was attributed to hospitalisation, ranging from 49% to 80% of the total. The costs of surgery constituted 40–61% of inpatient costs. Indirect costs in inflammatory bowel diseases, unappreciated and often underestimated (considered by few authors and as a loss of work), are in fact important and may even exceed direct medical costs. Termedia Publishing House 2016-02-11 2016 /pmc/articles/PMC4814543/ /pubmed/27110304 http://dx.doi.org/10.5114/pg.2016.57883 Text en Copyright © 2016 Termedia http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Review Paper
Petryszyn, Paweł W.
Witczak, Izabela
Costs in inflammatory bowel diseases
title Costs in inflammatory bowel diseases
title_full Costs in inflammatory bowel diseases
title_fullStr Costs in inflammatory bowel diseases
title_full_unstemmed Costs in inflammatory bowel diseases
title_short Costs in inflammatory bowel diseases
title_sort costs in inflammatory bowel diseases
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814543/
https://www.ncbi.nlm.nih.gov/pubmed/27110304
http://dx.doi.org/10.5114/pg.2016.57883
work_keys_str_mv AT petryszynpawełw costsininflammatoryboweldiseases
AT witczakizabela costsininflammatoryboweldiseases